{"title":"鼻甲注射肉毒杆菌毒素治疗慢性鼻炎。","authors":"Do H Kim, David W Jang, Se H Hwang","doi":"10.1002/lary.31936","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This systemic review with meta-analysis evaluated the effect of intranasal BTX-A turbinate injection on chronic rhinitis-related symptoms.</p><p><strong>Data sources: </strong>PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases.</p><p><strong>Review methods: </strong>We reviewed studies retrieved from databases up to Aug 2024. The studies evaluating the degree of change of rhinitis-related symptom scores and quality of life before and after BTX-A injection were analyzed. Standard mean differences were used to calculate effect sizes.</p><p><strong>Results: </strong>A total of 269 patients from 7 studies were analyzed. BTX-A injection showed a significant improvement in rhinitis-related symptoms (congestion: 2.5416, 95% CI 1.0927-3.9905, I<sup>2</sup> = 94.4%, itching: 1.2553, 95% CI 0.6660-1.8446; I<sup>2</sup> = 70.8%, rhinorrhea: 1.8451, 95% CI 1.0468-2.6435, I<sup>2</sup> = 89.7%, and sneezing: 1.3580, 95% CI 0.5194-2.1967; I<sup>2</sup> = 90.7%), total nasal symptom score (2.4020, 95% CI 1.4161-3.3879, I<sup>2</sup> = 86.1%), and quality of life (1.5256, 95% CI 1.0760-1.9752; I<sup>2</sup> = 0.0%) throughout the follow-up period (4 months). However, 3 months after injection, although symptom improvement remained, there was no statistical significance. Allergic rhinitis (AR) patients showed a significant improvement in rhinitis-related symptoms compared with nonallergic rhinitis (NAR) patients.</p><p><strong>Conclusions: </strong>Nasal symptoms and quality of life scores related to rhinitis were decreased after BTX-A injection. In particular, this treatment showed better efficacy in AR and could be more beneficial for the symptoms of nasal congestion and rhinorrhea at the early periods of treatment. However, the effects lasted for a relatively short period of only 2-3 months. Laryngoscope, 2024.</p>","PeriodicalId":49921,"journal":{"name":"Laryngoscope","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Turbinate Injection of Botulinum Toxin in the Treatment of the Chronic Rhinitis.\",\"authors\":\"Do H Kim, David W Jang, Se H Hwang\",\"doi\":\"10.1002/lary.31936\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This systemic review with meta-analysis evaluated the effect of intranasal BTX-A turbinate injection on chronic rhinitis-related symptoms.</p><p><strong>Data sources: </strong>PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases.</p><p><strong>Review methods: </strong>We reviewed studies retrieved from databases up to Aug 2024. The studies evaluating the degree of change of rhinitis-related symptom scores and quality of life before and after BTX-A injection were analyzed. Standard mean differences were used to calculate effect sizes.</p><p><strong>Results: </strong>A total of 269 patients from 7 studies were analyzed. BTX-A injection showed a significant improvement in rhinitis-related symptoms (congestion: 2.5416, 95% CI 1.0927-3.9905, I<sup>2</sup> = 94.4%, itching: 1.2553, 95% CI 0.6660-1.8446; I<sup>2</sup> = 70.8%, rhinorrhea: 1.8451, 95% CI 1.0468-2.6435, I<sup>2</sup> = 89.7%, and sneezing: 1.3580, 95% CI 0.5194-2.1967; I<sup>2</sup> = 90.7%), total nasal symptom score (2.4020, 95% CI 1.4161-3.3879, I<sup>2</sup> = 86.1%), and quality of life (1.5256, 95% CI 1.0760-1.9752; I<sup>2</sup> = 0.0%) throughout the follow-up period (4 months). However, 3 months after injection, although symptom improvement remained, there was no statistical significance. Allergic rhinitis (AR) patients showed a significant improvement in rhinitis-related symptoms compared with nonallergic rhinitis (NAR) patients.</p><p><strong>Conclusions: </strong>Nasal symptoms and quality of life scores related to rhinitis were decreased after BTX-A injection. In particular, this treatment showed better efficacy in AR and could be more beneficial for the symptoms of nasal congestion and rhinorrhea at the early periods of treatment. However, the effects lasted for a relatively short period of only 2-3 months. Laryngoscope, 2024.</p>\",\"PeriodicalId\":49921,\"journal\":{\"name\":\"Laryngoscope\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-12-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laryngoscope\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/lary.31936\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laryngoscope","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/lary.31936","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的：本系统综述与荟萃分析评估鼻内注射BTX-A鼻甲对慢性鼻炎相关症状的影响。数据来源：PubMed， SCOPUS, Embase， Web of Science和Cochrane数据库。回顾方法：我们回顾了数据库中截至2024年8月的研究。分析BTX-A注射前后鼻炎相关症状评分及生活质量变化程度的研究。使用标准均值差来计算效应量。结果：共分析了7项研究的269例患者。BTX-A注射液显著改善鼻炎相关症状(充血：2.5416,95% CI 1.0927 ~ 3.9905, I2 = 94.4%，瘙痒：1.2553,95% CI 0.6660 ~ 1.8446；I2 = 70.8%，鼻漏：1.8451,95% CI 1.0468 ~ 2.6435, I2 = 89.7%，打喷嚏：1.3580,95% CI 0.5194 ~ 2.1967；I2 = 90.7%)、总鼻症状评分（2.4020,95% CI 1.4161 ~ 3.3879, I2 = 86.1%）和生活质量(1.5256,95% CI 1.0760 ~ 1.9752；I2 = 0.0%)，随访4个月。然而，注射后3个月，虽然症状有所改善，但无统计学意义。变应性鼻炎（AR）患者与非变应性鼻炎（NAR）患者相比，鼻炎相关症状有显著改善。结论：BTX-A注射后鼻炎相关症状及生活质量评分均有所降低。特别是这种治疗在AR中表现出更好的疗效，对于治疗早期鼻塞和鼻漏症状可能更有利。然而，效果持续的时间相对较短，只有2-3个月。喉镜,2024年。
Turbinate Injection of Botulinum Toxin in the Treatment of the Chronic Rhinitis.
Objectives: This systemic review with meta-analysis evaluated the effect of intranasal BTX-A turbinate injection on chronic rhinitis-related symptoms.
Data sources: PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases.
Review methods: We reviewed studies retrieved from databases up to Aug 2024. The studies evaluating the degree of change of rhinitis-related symptom scores and quality of life before and after BTX-A injection were analyzed. Standard mean differences were used to calculate effect sizes.
Results: A total of 269 patients from 7 studies were analyzed. BTX-A injection showed a significant improvement in rhinitis-related symptoms (congestion: 2.5416, 95% CI 1.0927-3.9905, I2 = 94.4%, itching: 1.2553, 95% CI 0.6660-1.8446; I2 = 70.8%, rhinorrhea: 1.8451, 95% CI 1.0468-2.6435, I2 = 89.7%, and sneezing: 1.3580, 95% CI 0.5194-2.1967; I2 = 90.7%), total nasal symptom score (2.4020, 95% CI 1.4161-3.3879, I2 = 86.1%), and quality of life (1.5256, 95% CI 1.0760-1.9752; I2 = 0.0%) throughout the follow-up period (4 months). However, 3 months after injection, although symptom improvement remained, there was no statistical significance. Allergic rhinitis (AR) patients showed a significant improvement in rhinitis-related symptoms compared with nonallergic rhinitis (NAR) patients.
Conclusions: Nasal symptoms and quality of life scores related to rhinitis were decreased after BTX-A injection. In particular, this treatment showed better efficacy in AR and could be more beneficial for the symptoms of nasal congestion and rhinorrhea at the early periods of treatment. However, the effects lasted for a relatively short period of only 2-3 months. Laryngoscope, 2024.
期刊介绍：
The Laryngoscope has been the leading source of information on advances in the diagnosis and treatment of head and neck disorders since 1890. The Laryngoscope is the first choice among otolaryngologists for publication of their important findings and techniques. Each monthly issue of The Laryngoscope features peer-reviewed medical, clinical, and research contributions in general otolaryngology, allergy/rhinology, otology/neurotology, laryngology/bronchoesophagology, head and neck surgery, sleep medicine, pediatric otolaryngology, facial plastics and reconstructive surgery, oncology, and communicative disorders. Contributions include papers and posters presented at the Annual and Section Meetings of the Triological Society, as well as independent papers, "How I Do It", "Triological Best Practice" articles, and contemporary reviews. Theses authored by the Triological Society’s new Fellows as well as papers presented at meetings of the American Laryngological Association are published in The Laryngoscope.
• Broncho-esophagology
• Communicative disorders
• Head and neck surgery
• Plastic and reconstructive facial surgery
• Oncology
• Speech and hearing defects
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
